account
search
search

Wyeth's Prevnar sales booming

  |   Nov. 4, 2004 at 1:10 PM
CHICAGO, Nov. 4 (UPI) -- Prevnar, the popular drug to prevent bacterial meningitis, is on course to make more than $1 billion this year, a report says.

Sales of Prevnar, made by the pharmaceutical giant Wyeth, soared 32 percent in the third quarter to $321 million, the Chicago Tribune said Thursday.

A recent financial statement indicated this came about in part because the company made upgrades and improvements to its manufacturing facilities over the last year.

Prevnar vaccine costs about $260 for the four-shot regimen given to infants and young children. A dose of flu vaccine, by contrast, fetches about $8.

Wyeth left the flu vaccine market entirely last year to focus resources on its more lucrative vaccine.

© 2004 United Press International, Inc. All Rights Reserved. Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI's prior written consent.
x
Feedback